Patent: 10,053,498

Summary for Patent: 10,053,498

Title:	Compositions comprising serum albumin and p53 peptides fusion proteins
Abstract:	The present invention relates to compositions useful in inhibiting Bcl-XL or MCL-1 and disrupting p53-MDM2 and p53-MDMX interactions, and methods of using those compositions for treating a subject for conditions responsive to increasing p53 mediated activity or promoting p53 independent apoptosis, such as treating cancer. In some aspects, the compositions of this invention relate to fusion polypeptides comprising a human serum polypeptide and a p53-peptide, which can be, in some aspects, a p53 derived peptide and/or a p53 activating peptide.
Inventor(s):	Li; Zhiyu (Woodstock, MD), Parker; Michelle (Leander, TX)
Assignee:	University of the Sciences of Philadelphia (Philadelphia, PA)
Application Number:	14/948,010
Patent Claims:	see list of patent claims

Details for Patent 10,053,498

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Recordati Rare Diseases, Inc.	ELSPAR	asparaginase	For Injection	101063	01/10/1978		2034-11-21
Clinigen, Inc.	PROLEUKIN	aldesleukin	For Injection	103293	05/05/1992		2034-11-21
Amgen, Inc.	NEUPOGEN	filgrastim	Injection	103353	02/20/1991		2034-11-21
Amgen, Inc.	NEUPOGEN	filgrastim	Injection	103353	06/28/2000		2034-11-21
Partner Therapeutics, Inc.	LEUKINE	sargramostim	For Injection	103362	03/05/1991		2034-11-21
Partner Therapeutics, Inc.	LEUKINE	sargramostim	Injection	103362	03/05/1991		2034-11-21
Wyeth Pharmaceuticals Inc.	NEUMEGA	oprelvekin	For Injection	103694	11/25/1997		2034-11-21